Roivant reports top-line data from IMVT-1402 CLE trial
This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance